N/A
N=22
Assessment of nanOss Bioactive 3D in the Posterolateral Spine
Degenerative Disc Disease · Spinal Stenosis · Spondylolisthesis
Bottom Line
View on ClinicalTrials.gov: NCT01829997 ↗Enrolled (actual)
22
Serious AEs
13.6%
Results posted
Apr 2019
Primary outcome: Primary: Number of Patients With Fusion — 16 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- nanOss Bioactive 3D BVF (Device)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Pioneer Surgical Technology, Inc.
- Primary completion
- Apr 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Fusion |
16 | — |
| SECONDARY Number of Participants With Improvement in Quality of Life |
16 | — |
| SECONDARY Number of Participants With Improvement in Pain Scores |
18 | — |
| SECONDARY Number of Participants With Decreased Usage of Pain Medication |
— | — |
| SECONDARY Returning to Work |
— | — |
| SECONDARY Satisfaction With Surgery |
18 | — |
Summary
Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most widely used. However, complications can develop when the bone graft material used is insufficient to achieve the desired fusion. With its unique properties, nanOss Bioactive 3D can be mixed with bone marrow aspirate (BMA) and autograft bone to obtain new bone growth during the healing process.
nanOss Bioactive 3D is approved for use in the U.S., however, additional information is useful to assess its efficacy in the posterolateral spine. The purpose of this study is to assess fusion results in the posterolateral spine using nanOss Bioactive 3D mixed with autograft bone and BMA. It is hypothesized that the use of nanOss Bioactive 3D will result in fusion at 12 months, with CT evidence of bridging trabecular bone, less than 3mm of translational motion, and less than 5 degrees of angular motion.
Eligibility Criteria
Inclusion Criteria
- At least 21 years of age and skeletally mature.
- Symptomatic spinal stenosis secondary to DDD with up to Grade 1 spondylolisthesis at one or two adjacent levels from L2-S1 requiring instrumented PLF surgery.
- Completed a minimum of 6 months of non-operative treatment.
- Pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (AP, Lateral, Flexion and Extension images and an MRI or CT scan).
- Is willing and able to return for post-treatment exams according to the follow-up called for in the protocol.
- Is able to review, understand and sign the informed consent document.
Exclusion Criteria
- Symptomatic at more than two levels.
- Has had previous fusion surgery at the level(s) to be treated (previous discectomy, laminotomy, laminectomy or nucleolysis at the level(s) to be treated 11 degrees lumbar scoliosis.
- Has > 40 BMI.
- Has > Grade 1 spondylolisthesis.
- Has osteoporosis (T-score of -2.5 or below), osteomalacia, Paget's disease or metabolic bone disease.
- Has a disease that significantly inhibits bone healing (e.g., diabetes type 1, renal failure, impaired calcium metabolism).
- Has a medical condition that requires or has a history of chronic steroid use (i.e., oral steroids), with the exception of inhaled/nasal corticosteroids steroids or has any medical condition that requires treatment with drugs known to interfere with bone healing.
- Has a neurological disease (e.g., Parkinson's disease), a psychosocial disorder (e.g., suicidal, diminished capacity) or has a history of substance abuse which would preclude accurate evaluation or limit the ability to comply with study requirements.
- Has either an active infection or infection at the site of surgery
- Has a systemic disease (e.g., AIDS, HIV, active hepatitis, tuberculosis)
- Has rheumatoid arthritis or other autoimmune disease.
- Has spinal tumors.
- Has an active malignancy (except non-melanoma skin cancer) or history of any invasive malignancy unless treated and in remission for at least five years.
- Has a known sensitivity or allergies to porcine collagen, PEEK, tantalum or titanium.
- Has active arachnoiditis.
- Has fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
- Is a prisoner.
- Is involved in spinal litigation at the treated level(s).
- Is participating in another clinical study that would confound Study data.
- Is pregnant or is interested in becoming pregnant while participating in the Study.
Data sourced from ClinicalTrials.gov (NCT01829997). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.